Search
MSK researchers used the genome-editing tool CRISPR to create more potent chimeric antigen receptor (CAR) T cells that don't tire as easily when attacking cancer cells. The unexpected findings were published in the journal Nature on February 22 and underscore the potential of genome editing to advance immunotherapy for cancer.
On November 10, 2025, hundreds gathered in the Mortimer B. Zuckerman Research Center for the “MSK Innovation with Lasting Impact Summit: Entrepreneurship & Innovation at MSK,” at an event that brought together laboratory and clinical researchers, digital health innovators, healthcare executives, and investors.
Learn about MSK’s active surveillance program for papillary thyroid cancer, which allows many people to avoid unnecessary surgery and the risks that come with it.
Obtenga información sobre el programa de observación activa de MSK para el cáncer de tiroides papilar, que permite a muchas personas evitar cirugías innecesarias y los riesgos que estas tienen.
Though questions remain about how best to use genetic testing for cancer, the trend is toward more inclusive criteria.
Decades of research have shown that cancer survival outcomes can vary widely depending on where patients receive care. But efforts to rank hospitals by long-term survival rates have been hindered by the readily available administrative data derived from Medicare claims, which lacks information about cancer stage. Two hospitals providing equally good care may have different survival rates if one hospital treats sicker patients, for example.
Early CD4+ T cell reconstitution predicted non-relapsing mortality and overall survival in pediatric patients who received an allogeneic hematopoietic stem cell transplant (HCT) and developed acute graft-versus-host disease.
MSK experts believe that giving the targeted drug asciminib to patients with chronic myeloid leukemia at the beginning of their treatment offers them a better chance of being cured.
Third-year students Oakley Olsen and Alison Spencer have been named Grayer Fellows. Fellows are chosen based on excellence demonstrated by their thesis proposal examinations.
Former leader of Memorial Sloan Kettering Paul Marks gives a compelling view of cancer research and treatment over the past 40 years in On the Cancer Frontier: One Man, One Disease, and a Medical Revolution.